Daniel A Pollyea1, Craig T Jordan. 1. Department of Medicine, Division of Hematology, University of Colorado, Aurora, Colorado, USA.
Abstract
PURPOSE OF REVIEW: Venetoclax with backbone therapies have shown promising efficacy for newly diagnosed, previously untreated, older, unfit acute myeloid leukemia patients. This review discusses this data and potential reasons for the efficacy of these venetoclax-based combinations. RECENT FINDINGS: Venetoclax with hypomethylators and low-dose cytarabine have resulted in high response rates, promising response durations, and significant overall survival in relatively small, uncontrolled studies. There is emerging data that these responses are due to the effective targeting of leukemia stem cells through an alteration of the metabolic environment that is poorly tolerated by this population. SUMMARY: Venetoclax with a backbone therapy in older, untreated patients with acute myeloid leukemia has shown promising efficacy in preliminary clinical trials, and at least partially works through a novel mechanism that can target the leukemia stem cell population. Future investigations will help elucidate the mechanism and the contributions being made by each agent in the regimen.
PURPOSE OF REVIEW: Venetoclax with backbone therapies have shown promising efficacy for newly diagnosed, previously untreated, older, unfit acute myeloid leukemiapatients. This review discusses this data and potential reasons for the efficacy of these venetoclax-based combinations. RECENT FINDINGS:Venetoclax with hypomethylators and low-dose cytarabine have resulted in high response rates, promising response durations, and significant overall survival in relatively small, uncontrolled studies. There is emerging data that these responses are due to the effective targeting of leukemia stem cells through an alteration of the metabolic environment that is poorly tolerated by this population. SUMMARY:Venetoclax with a backbone therapy in older, untreated patients with acute myeloid leukemia has shown promising efficacy in preliminary clinical trials, and at least partially works through a novel mechanism that can target the leukemia stem cell population. Future investigations will help elucidate the mechanism and the contributions being made by each agent in the regimen.
Authors: Je-Hwan Lee; Stefan Faderl; John M Pagel; Chul Won Jung; Sung-Soo Yoon; Animesh D Pardanani; Pamela S Becker; Howard Lee; Jeongeun Choi; Kyoungjune Lee; Minkyoung Kim; Jorge E Cortes Journal: Blood Adv Date: 2020-05-12
Authors: Takenobu Nii; Varun V Prabhu; Vivian Ruvolo; Neel Madhukar; Ran Zhao; Hong Mu; Lauren Heese; Yuki Nishida; Kensuke Kojima; Mathew J Garnett; Ultan McDermott; Cyril H Benes; Neil Charter; Sean Deacon; Olivier Elemento; Joshua E Allen; Wolfgang Oster; Martin Stogniew; Jo Ishizawa; Michael Andreeff Journal: Leukemia Date: 2019-05-24 Impact factor: 11.528